HSBC Upgrades Teva Pharmaceutical (TEVA) to Overweight
More News related to TEVA
- Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets
- Teva (TEVA) and Antares (AIS) Announce FDA Approval of Needle-Free Injector for Tev-Tropin(R)
- Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin(R) (Human Growth Hormone)
- Teva Pharmaceutical (TEVA) and Active Biotech Complete Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
- Teva Pharma (TEVA) and Active Biotech Complete Patient Enrollment for Second Pivotal Phase III Trial of Laquinimod
HSBC upgrades Teva Pharmaceutical (Nasdaq: TEVA) from Neutral to Overweight.
Teva Pharmaceutical Industries Ltd. is a Global pharmaceutical company that develops, produces and markets generic drugs covering all major treatment categories.
Related Categories
UpgradesStocks Mentioned
-0.49Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
